Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 401

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 401
---
| Year ended 31 December 2022 |     | US Dollar £’000 |     | Euro £’000 |   |     | Other £’000 |
|:----------------------------|:----|----------------:|:----|:-----------|:--|:----|:------------|
| Loss before tax             |     |              25 |     | (1         | ) |     | –           |
| Total equity                |     |              25 |     | (1         | ) |     | –           |

| Year ended 31 December 2021 |     | US Dollar £’000 |     | Euro £’000 |     | Other £’000 |
|:----------------------------|:----|:----------------|:----|-----------:|:----|:------------|
| Loss before tax             |     | –               |     |          2 |     | –           |
| Total equity                |     | –               |     |          2 |     | –           |

| F-64 |

| 19 | Financial instruments – risk management (continued) |

Liquidity risk

Liquidity risk arises
from the Group’s management of working capital. It is the risk that the Group will encounter difficulty in meeting its financial
obligations as they fall due. It is the Group’s aim to settle balances as they become due.

In February 2023, the
Company completed a Private Placement in the US which raised £5.0million before expenses. In May 2023, the Company completed a Registered
Direct Offering in the US which raised £2.7million before expenses. In December 2023, the Company completed a Registered Offering
in the US which raised £4.4million before expenses.

In December 2022, the
Company completed a Registered Direct Offering in the US which raised £0.3million before expenses.

In February 2021, previously
issued warrants were exercised resulting in the Company receiving £0.13million before expenses. In July 2021, the Company completed
a UK placing which raised £10.0million before expenses.

The Directors have prepared cash flow forecasts and
considered the cash flow requirement for the Group for the next three years including the period 12 months from the date of approval of
the consolidated financial statements. These forecasts show that further financing will be required before the fourth quarter of 2024
assuming, inter alia, that certain development programs and other operating activities continue as currently planned.